Table 3 Age distribution of patients with primary spine osseous tumors (years)
From: Epidemiological characteristics of primary spinal osseous tumors in Eastern China
Type of tumor | 0–10 | 11–20 | 21–30 | 31–40 | 41–50 | 51–60 | 61–70 | 71–80 | 81–90 | Total no. (%) |
|---|---|---|---|---|---|---|---|---|---|---|
No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | ||
Benign tumors | 14(1.2%) | 102(8.4%) | 122(10.1%) | 173(14.3%) | 136(11.2%) | 138(11.4%) | 76(6.3%) | 19(1.6%) | 0(0.0%) | 780(64.5%) |
Hemangioma | 1(0.0%) | 14(1.2%) | 18(1.5%) | 62(5.1%) | 78(6.5%) | 96(7.9%) | 53(4.4%) | 18(1.5%) | 0(0.0%) | 340(28.1%) |
Giant cell tumor | 0(0.0%) | 27(2.2%) | 50(4.1%) | 62(5.1%) | 32(2.6%) | 11(0.9%) | 8(0.7%) | 0(0.0%) | 0(0.0%) | 190(15.7%) |
Eosinophililc granuloma | 3(0.2%) | 23(1.9%) | 9(0.7%) | 5(0.4%) | 2(0.2%) | 5(0.4%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 47(3.9%) |
Osteoblastoma | 6(0.5%) | 11(0.9%) | 14(1.2%) | 11(0.9%) | 5(0.4%) | 6(0.5%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 53(4.4%) |
Fibroma | 0(0.0%) | 0(0.0%) | 4(0.3%) | 4(0.3%) | 2(0.2%) | 2(0.2%) | 3(0.2%) | 1(0.0%) | 0(0.0%) | 16(1.3%) |
Osteoid osteoma | 0(0.0%) | 5(0.4%) | 3(0.2%) | 2(0.2%) | 2(0.2%) | 3(0.2%) | 2(0.2%) | 0(0.0%) | 0(0.0%) | 17(1.4%) |
Osteochondroma | 2(0.2%) | 12(1.0%) | 8(0.7%) | 9(0.7%) | 5(0.4%) | 5(0.4%) | 5(0.4%) | 0(0.0%) | 0(0.0%) | 46(3.8%) |
Solitary bone cyst | 0(0.0%) | 2(0.2%) | 3(0.2%) | 5(0.4%) | 6(0.5%) | 6(0.5%) | 3(0.2%) | 0(0.0%) | 0(0.0%) | 25(2.1%) |
Lipoma | 0(0.0%) | 0(0.0%) | 2(0.2%) | 3(0.2%) | 1(0.0%) | 1(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 7(0.6%) |
Aneurysmal bone cyst | 2(0.2%) | 8(0.7%) | 9(0.7%) | 8(0.7%) | 3(0.2%) | 3(0.2%) | 2(0.2%) | 0(0.0%) | 0(0.0%) | 35(2.9%) |
Fibrous dysplasia | 0(0.0%) | 0(0.0%) | 2(0.2%) | 2(0.2%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 4(0.3%) |
Malignant tumors | 5(0.4%) | 17(1.4%) | 36(3.0%) | 81(6.7%) | 95(7.9%) | 79(6.5%) | 82(6.8%) | 32(2.6%) | 2(0.2%) | 429(35.5%) |
PNET/Ewing’s sarcoma | 0(0.0%) | 5(0.4%) | 7(0.6%) | 3(0.2%) | 2(0.2%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 17(1.4%) |
Chordoma | 0(0.0%) | 0(0.0%) | 3(0.2%) | 17(1.4%) | 27(2.2%) | 23(1.9%) | 32(2.6%) | 15(1.2%) | 2(0.2%) | 119(9.8%) |
Malignant fibrous histiocytoma | 0(0.0%) | 0(0.0%) | 2(0.2%) | 0(0.0%) | 5(0.4%) | 6(0.5%) | 3(0.2%) | 0(0.0%) | 0(0.0%) | 16(1.3%) |
Liposarcoma | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 1(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 1(0.0%) |
Osteosarcoma | 0(0.0%) | 6(0.5%) | 2(0.2%) | 0(0.0%) | 3(0.2%) | 2(0.2%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 13(1.1%) |
Angiosarcoma | 0(0.0%) | 0(0.0%) | 0(0.0%) | 2(0.2%) | 3(0.2%) | 3(0.2%) | 1(0.0%) | 1(0.0%) | 0(0.0%) | 10(0.8%) |
Malignant neurilemmoma | 1(0.0%) | 1(0.0%) | 1(0.0%) | 9(0.7%) | 8(0.7%) | 5(0.4%) | 4(0.3%) | 1(0.0%) | 0(0.0%) | 30(2.5%) |
Plasma cell myeloma | 2(0.2%) | 0(0.0%) | 3(0.2%) | 17(1.4%) | 26(2.2%) | 22(1.8%) | 24(2.0%) | 9(0.7%) | 0(0.0%) | 103(8.5%) |
Leiomyosarcoma | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 1(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 1(0.0%) |
Malignant lymphoma | 2(0.2%) | 3(0.2%) | 6(0.5%) | 9(0.7%) | 12(1.0%) | 8(0.7%) | 8(0.7%) | 6(0.5%) | 0(0.0%) | 54(4.5%) |
Chondrosarcoma | 0(0.0%) | 2(0.2%) | 11(0.9%) | 24(2.0%) | 8(0.7%) | 9(0.7%) | 9(0.7%) | 0(0.0%) | 0(0.0%) | 63(5.2%) |
Fibrosarcoma | 0(0.0%) | 0(0.0%) | 1(0.0%) | 0(0.0%) | 0(0.0%) | 0(0.0%) | 1(0.0%) | 0(0.0%) | 0(0.0%) | 2(0.2%) |
Total | 19(1.6%) | 119(9.8%) | 158(13.1%) | 254(21.0%) | 231(19.1%) | 217(17.9%) | 158(13.1%) | 51(4.2%) | 2(0.2%) | 1209(100%) |